Well there is the existing business. Last quarter had some one time effects that hurt (taxes, consultant fee). Several insider buys in the 11-12 range. I have added.
First the deal will not be completed until 2016 so you have to wait to get 235.
Second there is a very small risk the deal will not be completed. Practically zero in my view. Also there will not be a higher bidder.
Can't do the math without knowing the royalty rates, I hope they are higher than in the past.
Announced. I am assuming they are getting better royalty rates on these newer deals. Rates were quite bad on the early deals.
With Baxter, Roche, Pfizer , JNJ and now Abbvie, can Amgen be far behind?